According to the research report titled ‘Antiviral Drugs Market Size By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Indication (Influenza, HIV AIDS, Hepatitis, Herpes Simplex Virus [HSV], Coronavirus Infection), By Type (Branded, Generic), By Age Group (Pediatric, Adult, Geriatric), Industry Analysis Report, Regional Outlook, Type Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027,’ available with MarketStudyReport, global antiviral drugs market is expected to witness robust expansion during the period 2021-2027. 
 

The rising prevalence of viral infections like COVID-19 as well as sexually transmitted diseases (STDs) and seasonal flu, particularly in the U.S., increasing geriatric population, and numerous products available for the treatment of HIV are factors augmenting the global antiviral drugs industry. 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/3692095/

For those unaware, antiviral drugs are prescribed medicines that fight against viruses in the body effectively. They are available in powder, liquid, and pill form, and on consumption, they reduce the danger of flu symptoms. 

During the COVID-19 pandemic, given the intensity of the outbreak, there was a huge boost in the demand for antiviral drugs like Remdesivir which was used to treat the coronavirus. Notably, in the National Center for Health Statistics (NCHS) mortality surveillance data released on 25^th February 2021, it was reported that in the week ending on 20th February 2021, 19.3% of people in the world died due to either Covid-19, influenza, or pneumonia. 

Despite the positive outlook, resistance among the people for consumption of drugs, and availability of generic medicines are likely to impede the progress of the market in the forthcoming years. 

In terms of drug class, the others segment of worldwide antiviral drugs industry was valued at USD 5 billion in the year 2020 and is estimated to observe remarkable growth during the analysis period, attributed to the surging use of combination therapy for effective treatment. 

Based on indication, the influenza vertical is anticipated to display sluggish growth during the review period, due to the rapid occurrence of the flu in countries like the U.S., along with its changing variants that calls for the requirement of new drugs. 

Speaking of type ambit, the branded segment held 70% industry share in 2020 and is reckoned to gain traction in the coming years, on account of better efficacy of branded drugs.

Concerning age group, the adult segment accounted for 32% market share in 2020 and is predicted to showcase substantial expansion during the study period, owing to the surging prevalence of STDs in the adult population, coupled with the significant cost of therapy. 

From a geographical view, North America antiviral drugs market is poised to register notable growth during the assessment timeframe, owing to a huge proportion of population suffering from the COVID-19 virus, combined with the presence of renowned COVID-19 and HIV drug manufacturers in the region. 

The prominent industry players defining the competitive landscape are Mylan N.V., Gilead Sciences, Inc., Cipla Ltd., Johnson & Johnson, Sun Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Aurobindo Pharma Limited, Bristol Myers Squibb, AbbVie, Inc., and Merck & Co. among others.